Enhancing effect of cadmium on rat ventral prostate carcinogenesis induced by 3,2'-dimethyl-4-aminobiphenyl.
The effects of cadmium given at different stages during 3,2'-dimethyl-4-aminobiphenyl (DMAB)-induced rat prostate carcinogenesis were investigated using male F344 rats. Animals were given 10 subcutaneous injections of 50 mg/kg body weight of DMAB or the corn oil vehicle at two-week intervals. In addition, cadmium was administered at doses of 0, 10, or 30 mumol/kg body weight as single intramuscular injection on the 1st day of the experiment or one day after the last injection of DMAB at week 20. Two further groups were subjected to administration of cadmium at 10 mumol/kg at week 20 and then 5 mumol/kg at week 40, or 10 mumol/kg at week 20 and then 5 mumol/kg at weeks 30, 40 and 50. At the termination, 60 weeks after the beginning of the experiment, the incidences and multiplicity of ventral prostate carcinomas in the groups given cadmium plus DMAB demonstrated a consistent tendency for increase over control values (groups receiving DMAB or cadmium alone). The numbers of carcinomas per rat and per unit area of prostate section were significantly elevated in the two groups given low doses of cadmium after cessation of DMAB administration. Cadmium alone also induced a few prostate carcinomas. The influence on development of prostate tumors did not appear to be a result of the induced severe testicular atrophy because serum testosterone levels were not affected. The results indicate that cadmium and DMAB can act synergistically to cause rat prostate carcinogenesis.
Shirai
T
T
First Department of Pathology, Nagoya City University Medical School.
Iwasaki
S
S
Masui
T
T
Mori
T
T
Kato
T
T
Ito
N
N
D000611:Aminobiphenyl Compounds / Q000008:administration & dosage; D000818:Animals; D001284:Atrophy; D001835:Body Weight; D002104:Cadmium / Q000494:pharmacology*; D002273:Carcinogens; D002277:Carcinoma / Q000139:chemically induced* / Q000401:mortality / Q000473:pathology; D003043:Cocarcinogenesis; D004334:Drug Administration Schedule; D004357:Drug Synergism; D008297:Male; D009929:Organ Size; D011467:Prostate / Q000187:drug effects / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000139:chemically induced; D011471:Prostatic Neoplasms / Q000139:chemically induced* / Q000401:mortality / Q000473:pathology; D051381:Rats; D011916:Rats, Inbred F344; D013739:Testosterone / Q000097:blood
D000611:Aminobiphenyl Compounds; D002273:Carcinogens; D002104:Cadmium; C001042:2',3-dimethyl-4-aminobiphenyl; D013739:Testosterone